Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1

References

• Nelson EA, Walker SR, Frank DA. Signaling in the pathogenesis and treatment of multiple myeloma. In: Munshi NC, Anderson KC, editors. Advances in biology and therapy of multiple myeloma, Vol. 2. New York, NY: Springer; 2013. pp 117–138.
   Google Scholar
• Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000;19:5662–5679.
   PubMed Web of Science ®Google Scholar
• Shy Y, Xu C. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases. Recent Pat DNA Gene Seq 2008;2:209–213.
   PubMedGoogle Scholar
• Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008;205:751–758.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008;19:385–393.
   PubMed Web of Science ®Google Scholar
• Gailkwad A, Rye CL, Devidas M, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009;144:930–932.
   PubMed Web of Science ®Google Scholar
• Huang Q, Li X, Chen W, Weiss LM. Absence of JAK-2V617F point mutations in multiple myeloma. Leukemia 2007;21:813–814.
   PubMed Web of Science ®Google Scholar
• Gordon GM, Lambert QT, Daniel KG, et al. Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ. Biochem J 2010;432:255–265.
   PubMed Web of Science ®Google Scholar
• Hornakova T, Chiaretti S, Lemaire MM, et al. ALL associated-JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood 2010;115:3287–3295.
   PubMed Web of Science ®Google Scholar
• Li J, Favata M, Kelley JA, et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia 2010;12:28–38.
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–757.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International Staging System for multiple myeloma. J Clin Oncol 2005;23:3412–3420.
   PubMed Web of Science ®Google Scholar
• Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleid Acids Symp Ser 1999;41:95–98.
   Google Scholar
• Sagawa M, Nakazato T, Uchida H, et al. Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway. Cancer Sci 2008;99:1820–1826.
   PubMed Web of Science ®Google Scholar
• Che Y, Hou S, Kang Z, et al. Serenoa repens induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of STAT3 signaling. Oncol Rep 2009;22:3777–3783.
   Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471: 467–472.
   PubMed Web of Science ®Google Scholar
• Cenci S, Sitia R. Managing and exploiting stress in the antibody factory. FEBS Lett 2007;581:3652–3657.
   PubMed Web of Science ®Google Scholar
• Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008;8:663–674.
   PubMed Web of Science ®Google Scholar
• Masciarelli S, Fra AM, Pengo N, et al. CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. Mol Immunol 2010;47:1356–1365.
   PubMed Web of Science ®Google Scholar
• Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417–421.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131–144.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115–130.
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr. Transcriptional factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740–749.
   PubMed Web of Science ®Google Scholar
• Ihle JN. The STAT family in cytokine signaling. Curr Opin Cell Biol 2001;13:211–217.
   PubMed Web of Science ®Google Scholar
• Wu ZL, Song YQ, Shi YF, et al. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 2011;4:31.
   PubMed Web of Science ®Google Scholar
• Liby K, Voong N, Williams CR, et al. The synthetic triterpenoid CDDO-imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 2006; 12:4288–4293.
   Google Scholar
• Nelson EA, Walker SR, Kepich A, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008;112:5095–5102.
   PubMed Web of Science ®Google Scholar